Intrathecal baclofen for spasticity
Villanueva E, Anderson J
Record ID 32003000664
English
Authors' objectives:
This aim of this report was to assess whether intrathecal baclofen is beneficial in hereditary spastic paraplegia.
Authors' recommendations:
- One systematic review published in 1997 was retrieved. We found no studies on this topic published since 1997.
- The review examined the effectiveness of intrathecal baclofen on general severe spasticity. High-level evidence for hereditary spastic paraplegia is lacking.
- Data from 27 studies representing the experience of 490 patients is examined.
- Primary endpoints include changes in Ashworth and Penn scores, duration of follow-up, and dosage at last follow-up - Mean Ashworth scores decreased from 3.9 to 1.6 (p<0.001) - Mean Penn scores decreased from 3.5 to 0.7 (p<0.001) - Cumulative success of 78.1% was reported - Over 16 months, dosage increased by an average of 250% from baseline.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.med.monash.edu.au/healthservices/cce/evidence/
Year Published:
2000
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Baclofen
- Spastic Paraplegia, Hereditary
Contact
Organisation Name:
Centre for Clinical Effectiveness
Contact Address:
Monash Institute of Health Services Research, Block E, Monash Medical Centre, Locked Bag 29, Clayton, Victoria 3168, Australia. Tel: +61 3 9594 7505; Fax: +61 3 9594 7552.
Contact Name:
cce@med.monash.edu.au.
Contact Email:
cce@med.monash.edu.au.
Copyright:
Centre for Clinical Effectiveness (CCE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.